Trial reportLipids in health and disease2020
Chia (Salvia hispanica)-supplemented diet ameliorates non-alcoholic fatty liver disease and its metabolic abnormalities in humans.
Trial report in Lipids in health and disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03942822 (Effect of a Chia Supplemented Diet), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of a Chia Supplemented Diet (Salvia Hispanica) on the Cardiometabolic Risk Profile in Patients With NAFLD (Non Alcoholic Fatty Liver Disease)
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Effect of Intermittent Fasting on Lipid Profile, Anthropometric and Hepatic Markers in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review.Current vascular pharmacology · 2024Pooled it
- Genome-wide variation analysis of two Salvia hispanica L. genotypes and implication for associations with metabolic and adaptive traits.Journal, genetic engineering & biotechnology · 2026Article
- Dose-Dependent Anti-Obesity and Protective Effects of Chia (Food science & nutrition · 2026Article
- The effects of salvia hispanica (chia seeds) on insulin sensitivity, hematological inflammatory indices and liver function in obese patients with non-alcoholic fatty liver disease (NAFLD).Nutrition & metabolism · 2025Article
- Unraveling the Association Between Cheese Consumption and Non-Alcoholic Fatty Liver Disease: Insights From a Two-Sample Mendelian Randomization Analysis.Food science & nutrition · 2025Article
- NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials.International journal of molecular sciences · 2025Review
- Current strategies for nonalcoholic fatty liver disease treatment (Review).International journal of molecular medicine · 2024Review
- Evaluation of hematoprotective, hepatoprotective, and anti-inflammatory potentials of chia seed (Veterinary and animal science · 2024Article
- Nutritional Support for Liver Diseases.Nutrients · 2023Review
- Review
- Safety of the extension of use of partially defatted chia seed (EFSA journal. European Food Safety Authority · 2023Article
- What's New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).Journal of clinical medicine · 2023Review
- The Potential of Lamiaceae Herbs for Mitigation of Overweight, Obesity, and Fatty Liver: Studies and Perspectives.Molecules (Basel, Switzerland) · 2022Review
- The Current State of Knowledge onMolecules (Basel, Switzerland) · 2022Review
- Effects of Omega-3-Rich Pork Lard on Serum Lipid Profile and Gut Microbiome in C57BL/6NJ Mice.International journal of food science · 2022Article
- Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease.Nutrients · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) is a public health problem lacking an approved pharmacological treatment. Omega-3 fatty acids have shown to reverse NAFLD. Chia is a seed rich in α-linolenic acid (ALA), antioxidants, and fiber; therefore, it could be useful to treat NAFLD.
methodsIn a single arm experimental design study, the effect of 25 g/day of milled chia was assessed in 25 patients with NAFLD. After two weeks of dietary stabilization (basal condition) and eight weeks of a chia-supplemented isocaloric diet, liver:spleen attenuation index and visceral abdominal fat (VAF) were measured by computed tomography. Lipids, lipoproteins, free fatty acids (FFA), and ALA plasma concentrations were also determined.
resultsDietary chia supplementation induced an increase in plasma ALA concentration (75%) and dietary fiber (55%) consumption. After chia supplementation, VAF (9%), body weight (1.4%), total cholesterol (2.5%), non-high density lipoprotein cholesterol (3.2%), and circulating FFA (8%) decreased. Furthermore, NAFLD regressed in 52% of the treated patients (P < 0.05 for all).
conclusionsThe results of the present study show that 25 g/day of milled chia ameliorates NAFLD. Chia is an accessible vegetal source of omega-3 fatty acids, antioxidants, and fiber, which could have the potential to prevent metabolic abnormalities in NAFLD patients. Considering that there is no pharmacological treatment approved for NAFLD, the findings of the present study suggest that a chia-supplemented diet could be an innovative alternative to control this disease. RETROSPECTIVELY REGISTERED: https://clinicaltrials.gov/show/NCT03942822.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.